TDMS Study 96020-01 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) DATE: 03/03/04
EXPERIMENT: 96020 TEST: 01 TIME: 09:55:48
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: NO1-ES-75411 ROUTE: GAVAGE NTP C#: C96020
PATHOLOGIST: SELLS, DONALD CAS: TEFBINARYMIX
------------------------------------------------------------------------------------------------------------------------------------
FINAL #1
REASONS FOR REMOVAL: 25018 Dosing Accident
25019 Moribund Sacrifice
25020 Natural Death
25021 Terminal Sacrifice
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE 001 0 NG / 0 UG
INCLUDE 002 10 NG / 10 UG
INCLUDE 003 100 NG /100 UG
INCLUDE 005 300 NG /300 UG
INCLUDE 007 1000 NG/1000 UG
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) DATE: 03/03/04
EXPERIMENT: 96020 TEST: 01 TIME: 09:55:48
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1-ES-75411 ROUTE: GAVAGE NTP C#: C96020
PATHOLOGIST: SELLS, DONALD CAS: TEFBINARYMIX
Rats(SPRAGUE-DAWLEY)
-----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE
BASED ON NUMBER OF TISSUES EXAMINED. IN OTHER TISSUES/ORGANS RATES
ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.
---------------
Adrenal Cortex
Adrenal Medulla
Brain
Clitoral/Preputial Gland
Heart
Islets, Pancreatic
Kidney
Liver
Lung
Ovary
Pancreas
Parathyroid Gland
Pituitary Gland
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) DATE: 03/03/04
EXPERIMENT: 96020 TEST: 01 TIME: 09:55:48
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1-ES-75411 ROUTE: GAVAGE NTP C#: C96020
PATHOLOGIST: SELLS, DONALD CAS: TEFBINARYMIX
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF TEF EVALUATION (BINARY MIXTURE; PCB 126
===============================================================
Female Rats
------------
Organ Morphology
----- ----------
Liver Cholangiocarcinoma
Hepatocellular Adenoma
Hepatocellular Carcinoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Hepatocholangioma
Lung Cystic Keratinizing Epithelioma
Mammary Gland Carcinoma
Carcinoma or Adenoma
Fibroadenoma
Fibroma, Fibroadenoma or Adenoma
Fibroma, Fibroadenoma, Carcinoma, or Adenoma
Oral Cavity (Oral Mucosa, Tongue, Pharynx, Tooth, Gingiva)
Squamous Cell Carcinoma
Squamous Cell Carcinoma, Papilloma Squamous, or Papilloma
Oral Mucosa Squamous Cell Carcinoma
Pituitary Gland: Pars Distalis or Unspecified Site
Adenoma
Carcinoma or Adenoma
Thyroid Gland: C-Cell Adenoma
Carcinoma
Carcinoma or Adenoma
Uterus Sarcoma Stromal or Polyp Stromal
All Organs Benign Tumors
Malignant Tumors
===============================================================
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 1
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma Benign |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 3/52 (6%) 1/53 (2%) 4/52 (8%) 1/52 (2%) 1/51 (2%) |
|POLY-3 RATE (b) | 3/37.43 1/37.40 4/39.19 1/37.39 1/37.18 |
|POLY-3 PERCENT (g) | 8.0% 2.7% 10.2% 2.7% 2.7% |
|TERMINAL (d) | 2/21 (10%) 1/21 (5%) 2/22 (9%) 1/24 (4%) 0/24 (0%) |
|FIRST INCIDENCE | 664 729 (T) 636 729 (T) 314 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.239N P=0.311N P=0.511 P=0.279N P=0.302N |
|POLY 3 | P=0.255N P=0.304N P=0.525 P=0.304N P=0.306N |
|POLY 1.5 | P=0.261N P=0.305N P=0.515 P=0.306N P=0.312N |
|POLY 6 | P=0.250N P=0.301N P=0.535 P=0.300N P=0.299N |
|LOGISTIC REGRESSION| P=0.269N P=0.295N P=0.533 P=0.291N P=0.309N |
|COCH-ARM / FISHERS | P=0.266N P=0.302N P=0.500 P=0.309N P=0.316N |
|ORDER RESTRICTED | P=0.262N (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Intestine Small: Duodenum |
| Leiomyoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/53 (0%) 0/53 (0%) 2/53 (4%) 0/53 (0%) |
|POLY-3 RATE (b) | 0/38.18 0/37.40 0/39.03 2/37.47 0/36.47 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 5.3% 0.0% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 0/22 (0%) 1/24 (4%) 0/24 (0%) |
|FIRST INCIDENCE | --- --- --- 710 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.737 (e) (e) P=0.263 (e) |
|POLY 3 | P=0.706 (e) (e) P=0.232 (e) |
|POLY 1.5 | P=0.706 (e) (e) P=0.232 (e) |
|POLY 6 | P=0.708 (e) (e) P=0.234 (e) |
|LOGISTIC REGRESSION| P=0.724 (e) (e) P=0.240 (e) |
|COCH-ARM / FISHERS | P=0.724 (e) (e) P=0.248 (e) |
|ORDER RESTRICTED | P=0.213 (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 2
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Intestine Small: Site Unspecified |
| Leiomyoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/53 (0%) 0/53 (0%) 2/53 (4%) 0/53 (0%) |
|POLY-3 RATE (b) | 0/38.18 0/37.40 0/39.03 2/37.47 0/36.47 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 5.3% 0.0% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 0/22 (0%) 1/24 (4%) 0/24 (0%) |
|FIRST INCIDENCE | --- --- --- 710 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.737 (e) (e) P=0.263 (e) |
|POLY 3 | P=0.706 (e) (e) P=0.232 (e) |
|POLY 1.5 | P=0.706 (e) (e) P=0.232 (e) |
|POLY 6 | P=0.708 (e) (e) P=0.234 (e) |
|LOGISTIC REGRESSION| P=0.724 (e) (e) P=0.240 (e) |
|COCH-ARM / FISHERS | P=0.724 (e) (e) P=0.248 (e) |
|ORDER RESTRICTED | P=0.213 (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Liver |
| Cholangiocarcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/53 (0%) 1/52 (2%) 9/52 (17%) 30/51 (59%) |
|POLY-3 RATE (b) | 0/38.18 0/37.40 1/38.82 9/38.00 30/39.75 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 2.6% 23.7% 75.5% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 1/22 (5%) 7/24 (29%) 20/24 (83%) |
|FIRST INCIDENCE | --- --- 729 (T) 603 479 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) P=0.500 P=0.003 ** P<0.001 ** |
|POLY 3 | P<0.001 ** (e) P=0.503 P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** (e) P=0.501 P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** (e) P=0.506 P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) P=0.500 P=0.002 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** (e) P=0.495 P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 3
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/53 (0%) 3/52 (6%) 5/52 (10%) 27/51 (53%) |
|POLY-3 RATE (b) | 0/38.18 0/37.40 3/39.16 5/37.57 27/39.88 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 7.7% 13.3% 67.7% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 1/22 (5%) 4/24 (17%) 18/24 (75%) |
|FIRST INCIDENCE | --- --- 654 684 479 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) P=0.134 P=0.040 * P<0.001 ** |
|POLY 3 | P<0.001 ** (e) P=0.122 P=0.028 * P<0.001 ** |
|POLY 1.5 | P<0.001 ** (e) P=0.120 P=0.028 * P<0.001 ** |
|POLY 6 | P<0.001 ** (e) P=0.125 P=0.028 * P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) P=0.124 P=0.032 * P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** (e) P=0.118 P=0.027 * P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/53 (0%) 0/52 (0%) 0/52 (0%) 2/51 (4%) |
|POLY-3 RATE (b) | 0/38.18 0/37.40 0/38.82 0/37.39 2/36.26 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 5.5% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 0/22 (0%) 0/24 (0%) 2/24 (8%) |
|FIRST INCIDENCE | --- --- --- --- 729 (T) |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.025 * (e) (e) (e) P=0.257 |
|POLY 3 | P=0.017 * (e) (e) (e) P=0.225 |
|POLY 1.5 | P=0.017 * (e) (e) (e) P=0.224 |
|POLY 6 | P=0.017 * (e) (e) (e) P=0.227 |
|LOGISTIC REGRESSION| (e) (e) (e) (e) P=0.257 |
|COCH-ARM / FISHERS | P=0.018 * (e) (e) (e) P=0.238 |
|ORDER RESTRICTED | P=0.014 * (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 4
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/53 (0%) 3/52 (6%) 5/52 (10%) 27/51 (53%) |
|POLY-3 RATE (b) | 0/38.18 0/37.40 3/39.16 5/37.57 27/39.88 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 7.7% 13.3% 67.7% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 1/22 (5%) 4/24 (17%) 18/24 (75%) |
|FIRST INCIDENCE | --- --- 654 684 479 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) P=0.134 P=0.040 * P<0.001 ** |
|POLY 3 | P<0.001 ** (e) P=0.122 P=0.028 * P<0.001 ** |
|POLY 1.5 | P<0.001 ** (e) P=0.120 P=0.028 * P<0.001 ** |
|POLY 6 | P<0.001 ** (e) P=0.125 P=0.028 * P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) P=0.124 P=0.032 * P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** (e) P=0.118 P=0.027 * P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, |
| or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/53 (0%) 3/52 (6%) 5/52 (10%) 27/51 (53%) |
|POLY-3 RATE (b) | 0/38.18 0/37.40 3/39.16 5/37.57 27/39.88 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 7.7% 13.3% 67.7% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 1/22 (5%) 4/24 (17%) 18/24 (75%) |
|FIRST INCIDENCE | --- --- 654 684 479 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) P=0.134 P=0.040 * P<0.001 ** |
|POLY 3 | P<0.001 ** (e) P=0.122 P=0.028 * P<0.001 ** |
|POLY 1.5 | P<0.001 ** (e) P=0.120 P=0.028 * P<0.001 ** |
|POLY 6 | P<0.001 ** (e) P=0.125 P=0.028 * P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) P=0.124 P=0.032 * P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** (e) P=0.118 P=0.027 * P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 5
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Liver |
| Hepatocholangioma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/53 (0%) 0/52 (0%) 2/52 (4%) 6/51 (12%) |
|POLY-3 RATE (b) | 0/38.18 0/37.40 0/38.82 2/37.39 6/36.26 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 5.4% 16.6% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 0/22 (0%) 2/24 (8%) 6/24 (25%) |
|FIRST INCIDENCE | --- --- --- 729 (T) 729 (T) |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) P=0.257 P=0.020 * |
|POLY 3 | P<0.001 ** (e) (e) P=0.232 P=0.012 * |
|POLY 1.5 | P<0.001 ** (e) (e) P=0.231 P=0.012 * |
|POLY 6 | P<0.001 ** (e) (e) P=0.233 P=0.012 * |
|LOGISTIC REGRESSION| (e) (e) (e) P=0.257 P=0.020 * |
|COCH-ARM / FISHERS | P<0.001 ** (e) (e) P=0.243 P=0.012 * |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Lung |
| Cystic Keratinizing Epithelioma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/53 (0%) 0/52 (0%) 1/53 (2%) 11/52 (21%) |
|POLY-3 RATE (b) | 0/38.18 0/37.40 0/38.82 1/37.40 11/37.46 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 2.7% 29.4% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 0/22 (0%) 1/24 (4%) 7/24 (29%) |
|FIRST INCIDENCE | --- --- --- 729 (T) 606 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) P=0.517 P<0.001 ** |
|POLY 3 | P<0.001 ** (e) (e) P=0.496 P<0.001 ** |
|POLY 1.5 | P<0.001 ** (e) (e) P=0.495 P<0.001 ** |
|POLY 6 | P<0.001 ** (e) (e) P=0.498 P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) (e) P=0.517 P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** (e) (e) P=0.500 P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 6
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 2/53 (4%) 1/53 (2%) 0/53 (0%) 0/53 (0%) 0/53 (0%) |
|POLY-3 RATE (b) | 2/38.18 1/37.40 0/39.03 0/37.40 0/36.47 |
|POLY-3 PERCENT (g) | 5.2% 2.7% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 2/22 (9%) 1/21 (5%) 0/22 (0%) 0/24 (0%) 0/24 (0%) |
|FIRST INCIDENCE | 729 (T) 729 (T) --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.208N P=0.516N P=0.237N P=0.218N P=0.218N |
|POLY 3 | P=0.230N P=0.507N P=0.232N P=0.241N P=0.247N |
|POLY 1.5 | P=0.229N P=0.507N P=0.234N P=0.242N P=0.248N |
|POLY 6 | P=0.230N P=0.505N P=0.229N P=0.238N P=0.244N |
|LOGISTIC REGRESSION| P=0.208N P=0.516N (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.226N P=0.500N P=0.248N P=0.248N P=0.248N |
|ORDER RESTRICTED | P=0.052N (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 8/53 (15%) 4/53 (8%) 3/53 (6%) 2/53 (4%) 0/53 (0%) |
|POLY-3 RATE (b) | 8/39.17 4/38.30 3/39.78 2/38.16 0/36.47 |
|POLY-3 PERCENT (g) | 20.4% 10.4% 7.5% 5.2% 0.0% |
|TERMINAL (d) | 6/22 (27%) 3/21 (14%) 2/22 (9%) 1/24 (4%) 0/24 (0%) |
|FIRST INCIDENCE | 449 337 461 451 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.007N** P=0.196N P=0.096N P=0.039N* P=0.004N** |
|POLY 3 | P=0.010N* P=0.182N P=0.089N P=0.046N* P=0.005N** |
|POLY 1.5 | P=0.010N* P=0.184N P=0.093N P=0.048N* P=0.005N** |
|POLY 6 | P=0.010N* P=0.179N P=0.086N P=0.044N* P=0.004N** |
|LOGISTIC REGRESSION| P=0.010N* P=0.186N P=0.095N P=0.051N P=0.006N** |
|COCH-ARM / FISHERS | P=0.010N* P=0.179N P=0.101N P=0.046N* P=0.003N** |
|ORDER RESTRICTED | P<0.001N** (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 7
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 10/53 (19%) 5/53 (9%) 3/53 (6%) 2/53 (4%) 0/53 (0%) |
|POLY-3 RATE (b) | 10/39.17 5/38.30 3/39.78 2/38.16 0/36.47 |
|POLY-3 PERCENT (g) | 25.5% 13.1% 7.5% 5.2% 0.0% |
|TERMINAL (d) | 8/22 (36%) 4/21 (19%) 2/22 (9%) 1/24 (4%) 0/24 (0%) |
|FIRST INCIDENCE | 449 337 461 451 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.002N** P=0.143N P=0.033N* P=0.011N* P<0.001N** |
|POLY 3 | P=0.003N** P=0.132N P=0.029N* P=0.013N* P<0.001N** |
|POLY 1.5 | P=0.003N** P=0.135N P=0.031N* P=0.014N* P<0.001N** |
|POLY 6 | P=0.003N** P=0.127N P=0.026N* P=0.012N* P<0.001N** |
|LOGISTIC REGRESSION| P=0.004N** P=0.138N P=0.033N* P=0.016N* P<0.001N** |
|COCH-ARM / FISHERS | P=0.004N** P=0.132N P=0.036N* P=0.014N* P<0.001N** |
|ORDER RESTRICTED | P<0.001N** (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroadenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 40/53 (75%) 39/53 (74%) 40/53 (75%) 34/53 (64%) 12/53 (23%) |
|POLY-3 RATE (b) | 40/48.11 39/45.83 40/47.48 34/46.23 12/38.26 |
|POLY-3 PERCENT (g) | 83.1% 85.1% 84.2% 73.5% 31.4% |
|TERMINAL (d) | 16/22 (73%) 17/21 (81%) 17/22 (77%) 15/24 (63%) 7/24 (29%) |
|FIRST INCIDENCE | 345 296 254 254 479 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001N** P=0.553 P=0.522N P=0.209N P<0.001N** |
|POLY 3 | P<0.001N** P=0.510 P=0.555 P=0.178N P<0.001N** |
|POLY 1.5 | P<0.001N** P=0.566 P=0.584 P=0.166N P<0.001N** |
|POLY 6 | P<0.001N** P=0.456 P=0.508 P=0.204N P<0.001N** |
|LOGISTIC REGRESSION| P<0.001N** P=0.570N P=0.564N P=0.165N P<0.001N** |
|COCH-ARM / FISHERS | P<0.001N** P=0.500N P=0.589N P=0.145N P<0.001N** |
|ORDER RESTRICTED | P<0.001N** (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 8
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 40/53 (75%) 39/53 (74%) 40/53 (75%) 34/53 (64%) 12/53 (23%) |
|POLY-3 RATE (b) | 40/48.11 39/45.83 40/47.48 34/46.23 12/38.26 |
|POLY-3 PERCENT (g) | 83.1% 85.1% 84.2% 73.5% 31.4% |
|TERMINAL (d) | 16/22 (73%) 17/21 (81%) 17/22 (77%) 15/24 (63%) 7/24 (29%) |
|FIRST INCIDENCE | 345 296 254 254 479 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001N** P=0.553 P=0.522N P=0.209N P<0.001N** |
|POLY 3 | P<0.001N** P=0.510 P=0.555 P=0.178N P<0.001N** |
|POLY 1.5 | P<0.001N** P=0.566 P=0.584 P=0.166N P<0.001N** |
|POLY 6 | P<0.001N** P=0.456 P=0.508 P=0.204N P<0.001N** |
|LOGISTIC REGRESSION| P<0.001N** P=0.570N P=0.564N P=0.165N P<0.001N** |
|COCH-ARM / FISHERS | P<0.001N** P=0.500N P=0.589N P=0.145N P<0.001N** |
|ORDER RESTRICTED | P<0.001N** (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma, Carcinoma, or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 42/53 (79%) 41/53 (77%) 42/53 (79%) 35/53 (66%) 12/53 (23%) |
|POLY-3 RATE (b) | 42/48.88 41/46.73 42/48.23 35/47.00 12/38.26 |
|POLY-3 PERCENT (g) | 85.9% 87.7% 87.1% 74.5% 31.4% |
|TERMINAL (d) | 17/22 (77%) 18/21 (86%) 18/22 (82%) 15/24 (63%) 7/24 (29%) |
|FIRST INCIDENCE | 345 296 254 254 479 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001N** P=0.547 P=0.519N P=0.174N P<0.001N** |
|POLY 3 | P<0.001N** P=0.518 P=0.555 P=0.114N P<0.001N** |
|POLY 1.5 | P<0.001N** P=0.581 P=0.587 P=0.106N P<0.001N** |
|POLY 6 | P<0.001N** P=0.449 P=0.504 P=0.132N P<0.001N** |
|LOGISTIC REGRESSION| P<0.001N** P=0.569N P=0.571N P=0.109N P<0.001N** |
|COCH-ARM / FISHERS | P<0.001N** P=0.500N P=0.594N P=0.095N P<0.001N** |
|ORDER RESTRICTED | P<0.001N** (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 9
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Oral Cavity (Oral Mucosa, Tongue, Pharynx, Tooth, Gingiva) |
| Squamous Cell Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/53 (0%) 2/53 (4%) 5/53 (9%) 9/53 (17%) |
|POLY-3 RATE (b) | 0/38.18 0/37.40 2/40.06 5/38.73 9/39.63 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 5.0% 12.9% 22.7% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 0/22 (0%) 1/24 (4%) 0/24 (0%) |
|FIRST INCIDENCE | --- --- 491 479 563 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) P=0.242 P=0.043 * P=0.003 ** |
|POLY 3 | P<0.001 ** (e) P=0.247 P=0.031 * P=0.002 ** |
|POLY 1.5 | P<0.001 ** (e) P=0.243 P=0.030 * P=0.002 ** |
|POLY 6 | P<0.001 ** (e) P=0.252 P=0.033 * P=0.003 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) P=0.232 P=0.032 * P=0.002 ** |
|COCH-ARM / FISHERS | P<0.001 ** (e) P=0.248 P=0.028 * P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Oral Cavity (Oral Mucosa, Tongue, Pharynx, Tooth, Gingiva) |
| Squamous Cell Carcinoma, Papilloma Squamous, or Papilloma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/53 (0%) 2/53 (4%) 5/53 (9%) 9/53 (17%) |
|POLY-3 RATE (b) | 0/38.18 0/37.40 2/40.06 5/38.73 9/39.63 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 5.0% 12.9% 22.7% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 0/22 (0%) 1/24 (4%) 0/24 (0%) |
|FIRST INCIDENCE | --- --- 491 479 563 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) P=0.242 P=0.043 * P=0.003 ** |
|POLY 3 | P<0.001 ** (e) P=0.247 P=0.031 * P=0.002 ** |
|POLY 1.5 | P<0.001 ** (e) P=0.243 P=0.030 * P=0.002 ** |
|POLY 6 | P<0.001 ** (e) P=0.252 P=0.033 * P=0.003 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) P=0.232 P=0.032 * P=0.002 ** |
|COCH-ARM / FISHERS | P<0.001 ** (e) P=0.248 P=0.028 * P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 10
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Oral Mucosa |
| Squamous Cell Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/53 (0%) 2/53 (4%) 5/53 (9%) 9/53 (17%) |
|POLY-3 RATE (b) | 0/38.18 0/37.40 2/40.06 5/38.73 9/39.63 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 5.0% 12.9% 22.7% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 0/22 (0%) 1/24 (4%) 0/24 (0%) |
|FIRST INCIDENCE | --- --- 491 479 563 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) P=0.242 P=0.043 * P=0.003 ** |
|POLY 3 | P<0.001 ** (e) P=0.247 P=0.031 * P=0.002 ** |
|POLY 1.5 | P<0.001 ** (e) P=0.243 P=0.030 * P=0.002 ** |
|POLY 6 | P<0.001 ** (e) P=0.252 P=0.033 * P=0.003 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) P=0.232 P=0.032 * P=0.002 ** |
|COCH-ARM / FISHERS | P<0.001 ** (e) P=0.248 P=0.028 * P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Ovary |
| Granulosa Cell Tumor: Benign, Malignant, NOS |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 1/53 (2%) 0/53 (0%) 0/52 (0%) 2/52 (4%) 0/49 (0%) |
|POLY-3 RATE (b) | 1/38.18 0/37.40 0/38.82 2/37.39 0/35.41 |
|POLY-3 PERCENT (g) | 2.6% 0.0% 0.0% 5.4% 0.0% |
|TERMINAL (d) | 1/22 (5%) 0/21 (0%) 0/22 (0%) 2/24 (8%) 0/24 (0%) |
|FIRST INCIDENCE | 729 (T) --- --- 729 (T) --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.535N P=0.509N P=0.500N P=0.531 P=0.483N |
|POLY 3 | P=0.585N P=0.504N P=0.497N P=0.493 P=0.515N |
|POLY 1.5 | P=0.588N P=0.504N P=0.499N P=0.491 P=0.518N |
|POLY 6 | P=0.579N P=0.503N P=0.494N P=0.496 P=0.510N |
|LOGISTIC REGRESSION| P=0.535N (e) (e) P=0.531 (e) |
|COCH-ARM / FISHERS | P=0.585N P=0.500N P=0.505N P=0.493 P=0.520N |
|ORDER RESTRICTED | P=0.325N (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 11
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Pancreas |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 1/53 (2%) 1/52 (2%) 3/52 (6%) 1/50 (2%) |
|POLY-3 RATE (b) | 0/38.18 1/37.52 1/38.82 3/37.39 1/36.09 |
|POLY-3 PERCENT (g) | 0.0% 2.7% 2.6% 8.0% 2.8% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 1/22 (5%) 3/24 (13%) 0/24 (0%) |
|FIRST INCIDENCE | --- 698 729 (T) 729 (T) 654 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.536 P=0.492 P=0.500 P=0.135 P=0.468 |
|POLY 3 | P=0.494 P=0.496 P=0.503 P=0.114 P=0.489 |
|POLY 1.5 | P=0.486 P=0.496 P=0.501 P=0.114 P=0.485 |
|POLY 6 | P=0.506 P=0.499 P=0.506 P=0.115 P=0.494 |
|LOGISTIC REGRESSION| P=0.500 P=0.497 P=0.500 P=0.135 P=0.486 |
|COCH-ARM / FISHERS | P=0.494 P=0.500 P=0.495 P=0.118 P=0.485 |
|ORDER RESTRICTED | P=0.150 (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Pancreas |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 1/53 (2%) 1/52 (2%) 4/52 (8%) 2/50 (4%) |
|POLY-3 RATE (b) | 0/38.18 1/37.52 1/38.82 4/37.39 2/36.09 |
|POLY-3 PERCENT (g) | 0.0% 2.7% 2.6% 10.7% 5.5% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 1/22 (5%) 4/24 (17%) 1/24 (4%) |
|FIRST INCIDENCE | --- 698 729 (T) 729 (T) 654 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.277 P=0.492 P=0.500 P=0.072 P=0.231 |
|POLY 3 | P=0.226 P=0.496 P=0.503 P=0.056 P=0.224 |
|POLY 1.5 | P=0.221 P=0.496 P=0.501 P=0.057 P=0.221 |
|POLY 6 | P=0.236 P=0.499 P=0.506 P=0.057 P=0.229 |
|LOGISTIC REGRESSION| P=0.236 P=0.497 P=0.500 P=0.072 P=0.224 |
|COCH-ARM / FISHERS | P=0.229 P=0.500 P=0.495 P=0.057 P=0.233 |
|ORDER RESTRICTED | P=0.060 (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 12
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 22/53 (42%) 21/53 (40%) 17/53 (32%) 17/52 (33%) 1/52 (2%) |
|POLY-3 RATE (b) | 22/41.64 21/40.38 17/41.12 17/38.83 1/36.33 |
|POLY-3 PERCENT (g) | 52.8% 52.0% 41.3% 43.8% 2.8% |
|TERMINAL (d) | 13/22 (59%) 10/21 (48%) 11/22 (50%) 12/24 (50%) 0/24 (0%) |
|FIRST INCIDENCE | 418 563 499 506 714 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001N** P=0.541N P=0.212N P=0.168N P<0.001N** |
|POLY 3 | P<0.001N** P=0.560N P=0.195N P=0.271N P<0.001N** |
|POLY 1.5 | P<0.001N** P=0.558N P=0.199N P=0.268N P<0.001N** |
|POLY 6 | P<0.001N** P=0.528N P=0.195N P=0.268N P<0.001N** |
|LOGISTIC REGRESSION| P<0.001N** P=0.536N P=0.175N P=0.243N P<0.001N** |
|COCH-ARM / FISHERS | P<0.001N** P=0.500N P=0.210N P=0.232N P<0.001N** |
|ORDER RESTRICTED | P<0.001N** (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 23/53 (43%) 22/53 (42%) 17/53 (32%) 17/52 (33%) 1/52 (2%) |
|POLY-3 RATE (b) | 23/41.70 22/40.38 17/41.12 17/38.83 1/36.33 |
|POLY-3 PERCENT (g) | 55.2% 54.5% 41.3% 43.8% 2.8% |
|TERMINAL (d) | 13/22 (59%) 11/21 (52%) 11/22 (50%) 12/24 (50%) 0/24 (0%) |
|FIRST INCIDENCE | 418 563 499 506 714 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001N** P=0.543N P=0.162N P=0.126N P<0.001N** |
|POLY 3 | P<0.001N** P=0.567N P=0.139N P=0.203N P<0.001N** |
|POLY 1.5 | P<0.001N** P=0.562N P=0.145N P=0.203N P<0.001N** |
|POLY 6 | P<0.001N** P=0.536N P=0.138N P=0.199N P<0.001N** |
|LOGISTIC REGRESSION| P<0.001N** P=0.537N P=0.126N P=0.182N P<0.001N** |
|COCH-ARM / FISHERS | P<0.001N** P=0.500N P=0.158N P=0.177N P<0.001N** |
|ORDER RESTRICTED | P<0.001N** (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 13
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Intermedia |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/53 (0%) 2/53 (4%) 0/52 (0%) 0/52 (0%) |
|POLY-3 RATE (b) | 0/38.18 0/37.40 2/39.87 0/36.79 0/36.27 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 5.0% 0.0% 0.0% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 0/22 (0%) 0/24 (0%) 0/24 (0%) |
|FIRST INCIDENCE | --- --- 461 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.479N (e) P=0.262 (e) (e) |
|POLY 3 | P=0.489N (e) P=0.246 (e) (e) |
|POLY 1.5 | P=0.493N (e) P=0.243 (e) (e) |
|POLY 6 | P=0.485N (e) P=0.250 (e) (e) |
|LOGISTIC REGRESSION| P=0.484N (e) P=0.234 (e) (e) |
|COCH-ARM / FISHERS | P=0.494N (e) P=0.248 (e) (e) |
|ORDER RESTRICTED | P=0.398 (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Skin |
| Basal Cell Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 0/53 (0%) 2/53 (4%) 0/53 (0%) 0/53 (0%) 1/53 (2%) |
|POLY-3 RATE (b) | 0/38.18 2/37.83 0/39.03 0/37.40 1/37.45 |
|POLY-3 PERCENT (g) | 0.0% 5.3% 0.0% 0.0% 2.7% |
|TERMINAL (d) | 0/22 (0%) 1/21 (5%) 0/22 (0%) 0/24 (0%) 0/24 (0%) |
|FIRST INCIDENCE | --- 603 --- --- 181 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.604 P=0.235 (e) (e) P=0.492 |
|POLY 3 | P=0.599 P=0.234 (e) (e) P=0.496 |
|POLY 1.5 | P=0.598 P=0.233 (e) (e) P=0.495 |
|POLY 6 | P=0.603 P=0.237 (e) (e) P=0.499 |
|LOGISTIC REGRESSION| P=0.651 P=0.234 (e) (e) P=0.694 |
|COCH-ARM / FISHERS | P=0.607 P=0.248 (e) (e) P=0.500 |
|ORDER RESTRICTED | P=0.303 (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 14
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Skin |
| Basal or Sq. Cell Carcinoma, Carcinoma, Basosq. Tumor |
| (M or B), Basal Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepitheliom |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 0/53 (0%) 2/53 (4%) 1/53 (2%) 0/53 (0%) 1/53 (2%) |
|POLY-3 RATE (b) | 0/38.18 2/37.83 1/39.86 0/37.40 1/37.45 |
|POLY-3 PERCENT (g) | 0.0% 5.3% 2.5% 0.0% 2.7% |
|TERMINAL (d) | 0/22 (0%) 1/21 (5%) 0/22 (0%) 0/24 (0%) 0/24 (0%) |
|FIRST INCIDENCE | --- 603 407 --- 181 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.679 P=0.235 P=0.504 (e) P=0.492 |
|POLY 3 | P=0.677 P=0.234 P=0.509 (e) P=0.496 |
|POLY 1.5 | P=0.676 P=0.233 P=0.505 (e) P=0.495 |
|POLY 6 | P=0.680 P=0.237 P=0.511 (e) P=0.499 |
|LOGISTIC REGRESSION| P=0.607N P=0.234 P=0.485 (e) P=0.694 |
|COCH-ARM / FISHERS | P=0.677N P=0.248 P=0.500 (e) P=0.500 |
|ORDER RESTRICTED | P=0.365 (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Skin |
| Fibroma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 2/53 (4%) 1/53 (2%) 3/53 (6%) 1/53 (2%) 0/53 (0%) |
|POLY-3 RATE (b) | 2/38.47 1/37.40 3/39.33 1/37.66 0/36.47 |
|POLY-3 PERCENT (g) | 5.2% 2.7% 7.6% 2.7% 0.0% |
|TERMINAL (d) | 0/22 (0%) 1/21 (5%) 1/22 (5%) 0/24 (0%) 0/24 (0%) |
|FIRST INCIDENCE | 664 729 (T) 664 659 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.153N P=0.513N P=0.507 P=0.509N P=0.250N |
|POLY 3 | P=0.157N P=0.510N P=0.510 P=0.507N P=0.248N |
|POLY 1.5 | P=0.158N P=0.509N P=0.506 P=0.508N P=0.248N |
|POLY 6 | P=0.156N P=0.510N P=0.514 P=0.504N P=0.248N |
|LOGISTIC REGRESSION| P=0.156N P=0.505N P=0.512 P=0.506N P=0.246N |
|COCH-ARM / FISHERS | P=0.150N P=0.500N P=0.500 P=0.500N P=0.248N |
|ORDER RESTRICTED | P=0.196N (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 15
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Skin |
| Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, |
| or Fibrous Histiocytoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 2/53 (4%) 3/53 (6%) 4/53 (8%) 1/53 (2%) 1/53 (2%) |
|POLY-3 RATE (b) | 2/38.47 3/38.36 4/39.33 1/37.66 1/37.44 |
|POLY-3 PERCENT (g) | 5.2% 7.8% 10.2% 2.7% 2.7% |
|TERMINAL (d) | 0/22 (0%) 1/21 (5%) 2/22 (9%) 0/24 (0%) 0/24 (0%) |
|FIRST INCIDENCE | 664 407 664 659 206 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.204N P=0.483 P=0.346 P=0.509N P=0.517N |
|POLY 3 | P=0.208N P=0.499 P=0.346 P=0.507N P=0.509N |
|POLY 1.5 | P=0.209N P=0.496 P=0.343 P=0.508N P=0.511N |
|POLY 6 | P=0.206N P=0.504 P=0.348 P=0.504N P=0.508N |
|LOGISTIC REGRESSION| P=0.203N P=0.496 P=0.349 P=0.506N P=0.458N |
|COCH-ARM / FISHERS | P=0.201N P=0.500 P=0.339 P=0.500N P=0.500N |
|ORDER RESTRICTED | P=0.294N (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Skin |
| Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 0/53 (0%) 2/53 (4%) 1/53 (2%) 0/53 (0%) 1/53 (2%) |
|POLY-3 RATE (b) | 0/38.18 2/38.36 1/39.03 0/37.40 1/37.44 |
|POLY-3 PERCENT (g) | 0.0% 5.2% 2.6% 0.0% 2.7% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 1/22 (5%) 0/24 (0%) 0/24 (0%) |
|FIRST INCIDENCE | --- 407 729 (T) --- 206 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.671N P=0.231 P=0.500 (e) P=0.488 |
|POLY 3 | P=0.679 P=0.237 P=0.504 (e) P=0.496 |
|POLY 1.5 | P=0.677 P=0.235 P=0.503 (e) P=0.494 |
|POLY 6 | P=0.679N P=0.241 P=0.506 (e) P=0.499 |
|LOGISTIC REGRESSION| P=0.625N P=0.247 P=0.500 (e) P=0.678 |
|COCH-ARM / FISHERS | P=0.677N P=0.248 P=0.500 (e) P=0.500 |
|ORDER RESTRICTED | P=0.365 (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 16
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 10/53 (19%) 14/53 (26%) 16/51 (31%) 15/52 (29%) 7/52 (13%) |
|POLY-3 RATE (b) | 10/39.40 14/39.56 16/39.94 15/38.93 7/37.39 |
|POLY-3 PERCENT (g) | 25.4% 35.4% 40.1% 38.5% 18.7% |
|TERMINAL (d) | 7/22 (32%) 8/21 (38%) 11/22 (50%) 10/24 (42%) 4/24 (17%) |
|FIRST INCIDENCE | 426 499 603 499 485 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.047N* P=0.224 P=0.129 P=0.225 P=0.268N |
|POLY 3 | P=0.077N P=0.231 P=0.118 P=0.151 P=0.333N |
|POLY 1.5 | P=0.083N P=0.224 P=0.115 P=0.146 P=0.343N |
|POLY 6 | P=0.070N P=0.252 P=0.121 P=0.170 P=0.318N |
|LOGISTIC REGRESSION| P=0.079N P=0.220 P=0.132 P=0.146 P=0.335N |
|COCH-ARM / FISHERS | P=0.070N P=0.243 P=0.106 P=0.166 P=0.314N |
|ORDER RESTRICTED | P=0.094N (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 4/53 (8%) 0/53 (0%) 1/51 (2%) 1/52 (2%) 0/52 (0%) |
|POLY-3 RATE (b) | 4/39.21 0/37.40 1/38.82 1/36.79 0/36.27 |
|POLY-3 PERCENT (g) | 10.2% 0.0% 2.6% 2.7% 0.0% |
|TERMINAL (d) | 2/22 (9%) 0/21 (0%) 1/22 (5%) 1/24 (4%) 0/24 (0%) |
|FIRST INCIDENCE | 426 --- 729 (T) 729 (T) --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.140N P=0.070N P=0.182N P=0.169N P=0.063N |
|POLY 3 | P=0.152N P=0.065N P=0.180N P=0.196N P=0.069N |
|POLY 1.5 | P=0.154N P=0.065N P=0.182N P=0.196N P=0.070N |
|POLY 6 | P=0.150N P=0.065N P=0.179N P=0.195N P=0.069N |
|LOGISTIC REGRESSION| P=0.157N P=0.064N P=0.184N P=0.190N P=0.067N |
|COCH-ARM / FISHERS | P=0.152N P=0.059N P=0.194N P=0.187N P=0.061N |
|ORDER RESTRICTED | P=0.008N** (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 17
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | |
|----------- | |
|OVERALL (a) | 13/53 (25%) 14/53 (26%) 17/51 (33%) 16/52 (31%) 7/52 (13%) |
|POLY-3 RATE (b) | 13/39.63 14/39.56 17/39.94 16/38.93 7/37.39 |
|POLY-3 PERCENT (g) | 32.8% 35.4% 42.6% 41.1% 18.7% |
|TERMINAL (d) | 9/22 (41%) 8/21 (38%) 12/22 (55%) 11/24 (46%) 4/24 (17%) |
|FIRST INCIDENCE | 426 499 603 499 485 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.021N* P=0.470 P=0.259 P=0.400 P=0.091N |
|POLY 3 | P=0.036N* P=0.498 P=0.246 P=0.294 P=0.121N |
|POLY 1.5 | P=0.040N* P=0.484 P=0.241 P=0.284 P=0.128N |
|POLY 6 | P=0.033N* P=0.530 P=0.251 P=0.323 P=0.111N |
|LOGISTIC REGRESSION| P=0.038N* P=0.477 P=0.271 P=0.283 P=0.125N |
|COCH-ARM / FISHERS | P=0.035N* P=0.500 P=0.219 P=0.310 P=0.116N |
|ORDER RESTRICTED | P=0.050N (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Uterus |
| Polyp Stromal |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 8/53 (15%) 7/53 (13%) 7/53 (13%) 6/53 (11%) 3/53 (6%) |
|POLY-3 RATE (b) | 8/38.61 7/38.70 7/39.39 6/37.45 3/36.71 |
|POLY-3 PERCENT (g) | 20.7% 18.1% 17.8% 16.0% 8.2% |
|TERMINAL (d) | 5/22 (23%) 4/21 (19%) 5/22 (23%) 5/24 (21%) 2/24 (8%) |
|FIRST INCIDENCE | 640 534 659 715 665 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.056N P=0.520N P=0.490N P=0.330N P=0.088N |
|POLY 3 | P=0.087N P=0.498N P=0.483N P=0.407N P=0.109N |
|POLY 1.5 | P=0.088N P=0.507N P=0.489N P=0.407N P=0.112N |
|POLY 6 | P=0.086N P=0.481N P=0.477N P=0.405N P=0.105N |
|LOGISTIC REGRESSION| P=0.079N P=0.514N P=0.470N P=0.368N P=0.103N |
|COCH-ARM / FISHERS | P=0.075N P=0.500N P=0.500N P=0.388N P=0.101N |
|ORDER RESTRICTED | P=0.111N (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 18
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Uterus |
| Sarcoma Stromal or Polyp Stromal |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 8/53 (15%) 7/53 (13%) 8/53 (15%) 6/53 (11%) 3/53 (6%) |
|POLY-3 RATE (b) | 8/38.61 7/38.70 8/40.14 6/37.45 3/36.71 |
|POLY-3 PERCENT (g) | 20.7% 18.1% 19.9% 16.0% 8.2% |
|TERMINAL (d) | 5/22 (23%) 4/21 (19%) 5/22 (23%) 5/24 (21%) 2/24 (8%) |
|FIRST INCIDENCE | 640 534 458 715 665 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.049N* P=0.520N P=0.591N P=0.330N P=0.088N |
|POLY 3 | P=0.078N P=0.498N P=0.577N P=0.407N P=0.109N |
|POLY 1.5 | P=0.077N P=0.507N P=0.588N P=0.407N P=0.112N |
|POLY 6 | P=0.077N P=0.481N P=0.566N P=0.405N P=0.105N |
|LOGISTIC REGRESSION| P=0.071N P=0.514N P=0.587N P=0.368N P=0.103N |
|COCH-ARM / FISHERS | P=0.065N P=0.500N P=0.607N P=0.388N P=0.101N |
|ORDER RESTRICTED | P=0.115N (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Uterus |
| Schwannoma Malignant |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/53 (0%) 0/53 (0%) 2/53 (4%) 0/53 (0%) |
|POLY-3 RATE (b) | 0/38.18 0/37.40 0/39.03 2/38.71 0/36.47 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 5.2% 0.0% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 0/22 (0%) 0/24 (0%) 0/24 (0%) |
|FIRST INCIDENCE | --- --- --- 479 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.726 (e) (e) P=0.245 (e) |
|POLY 3 | P=0.705 (e) (e) P=0.239 (e) |
|POLY 1.5 | P=0.705 (e) (e) P=0.236 (e) |
|POLY 6 | P=0.706 (e) (e) P=0.246 (e) |
|LOGISTIC REGRESSION| P=0.733N (e) (e) P=0.257 (e) |
|COCH-ARM / FISHERS | P=0.724 (e) (e) P=0.248 (e) |
|ORDER RESTRICTED | P=0.220 (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 19
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|Uterus |
| Squamous Cell Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 1/53 (2%) 1/53 (2%) 1/53 (2%) 4/53 (8%) 0/53 (0%) |
|POLY-3 RATE (b) | 1/38.18 1/37.40 1/39.03 4/37.49 0/36.47 |
|POLY-3 PERCENT (g) | 2.6% 2.7% 2.6% 10.7% 0.0% |
|TERMINAL (d) | 1/22 (5%) 1/21 (5%) 1/22 (5%) 2/24 (8%) 0/24 (0%) |
|FIRST INCIDENCE | 729 (T) 729 (T) 729 (T) 715 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.344N P=0.753 P=0.763 P=0.211 P=0.483N |
|POLY 3 | P=0.397N P=0.757 P=0.757N P=0.171 P=0.509N |
|POLY 1.5 | P=0.397N P=0.756 P=0.758N P=0.171 P=0.510N |
|POLY 6 | P=0.394N P=0.759 P=0.755N P=0.173 P=0.507N |
|LOGISTIC REGRESSION| P=0.361N P=0.753 P=0.763 P=0.187 (e) |
|COCH-ARM / FISHERS | P=0.374N P=0.752N P=0.752N P=0.181 P=0.500N |
|ORDER RESTRICTED | P=0.249N (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, |
| NOS, or Undifferentiated Cell Type |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 0/53 (0%) 1/53 (2%) 2/53 (4%) 2/53 (4%) 2/53 (4%) |
|POLY-3 RATE (b) | 0/38.18 1/38.27 2/39.13 2/37.81 2/36.47 |
|POLY-3 PERCENT (g) | 0.0% 2.6% 5.1% 5.3% 5.5% |
|TERMINAL (d) | 0/22 (0%) 0/21 (0%) 1/22 (5%) 1/24 (4%) 2/24 (8%) |
|FIRST INCIDENCE | --- 367 705 612 729 (T) |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.328 P=0.488 P=0.252 P=0.240 P=0.257 |
|POLY 3 | P=0.287 P=0.500 P=0.242 P=0.234 P=0.226 |
|POLY 1.5 | P=0.288 P=0.499 P=0.240 P=0.233 P=0.226 |
|POLY 6 | P=0.288 P=0.503 P=0.244 P=0.238 P=0.228 |
|LOGISTIC REGRESSION| P=0.297 P=0.530 P=0.245 P=0.233 P=0.257 |
|COCH-ARM / FISHERS | P=0.310 P=0.500 P=0.248 P=0.248 P=0.248 |
|ORDER RESTRICTED | P=0.176 (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 20
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 49/53 (92%) 43/53 (81%) 48/53 (91%) 46/53 (87%) 36/53 (68%) |
|POLY-3 RATE (b) | 49/49.76 43/46.09 48/49.33 46/47.73 36/42.50 |
|POLY-3 PERCENT (g) | 98.5% 93.3% 97.3% 96.4% 84.7% |
|TERMINAL (d) | 22/22 (100%) 20/21 (95%) 22/22 (100%) 23/24 (96%) 22/24 (92%) |
|FIRST INCIDENCE | 345 296 254 254 314 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.021N* P=0.302N P=0.463N P=0.313N P=0.024N* |
|POLY 3 | P<0.001N** P=0.157N P=0.684N P=0.494N P=0.005N** |
|POLY 1.5 | P<0.001N** P=0.102N P=0.550N P=0.416N P=0.002N** |
|POLY 6 | P=0.004N** P=0.242N P=0.965N P=0.515N P=0.018N* |
|LOGISTIC REGRESSION| P<0.001N** P=0.099N P=0.450N P=0.411N P=0.002N** |
|COCH-ARM / FISHERS | P<0.001N** P=0.075N P=0.500N P=0.263N P<0.001N** |
|ORDER RESTRICTED | P<0.001N** (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 14/53 (26%) 18/53 (34%) 14/53 (26%) 23/53 (43%) 37/53 (70%) |
|POLY-3 RATE (b) | 14/40.90 18/43.06 14/41.95 23/42.72 37/44.23 |
|POLY-3 PERCENT (g) | 34.2% 41.8% 33.4% 53.8% 83.7% |
|TERMINAL (d) | 9/22 (41%) 8/21 (38%) 7/22 (32%) 11/24 (46%) 21/24 (88%) |
|FIRST INCIDENCE | 377 167 458 142 169 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.238 P=0.560N P=0.094 P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.308 P=0.560N P=0.049 * P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.284 P=0.574N P=0.044 * P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.350 P=0.538N P=0.065 P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.261 P=0.576N P=0.045 * P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.263 P=0.587N P=0.051 P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/03/04 EXPERIMENT: 96020 TEST: 01 Page 21
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (BINARY MIXTURE; PCB 126
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ |
| | 0 UG 10 UG 100 UG 300 UG 1000 UG |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 51/53 (96%) 49/53 (92%) 50/53 (94%) 50/53 (94%) 46/53 (87%) |
|POLY-3 RATE (b) | 51/51.39 49/50.84 50/50.78 50/50.20 46/48.11 |
|POLY-3 PERCENT (g) | 99.2% 96.4% 98.5% 99.6% 95.6% |
|TERMINAL (d) | 22/22 (100%) 20/21 (95%) 22/22 (100%) 24/24 (100%) 23/24 (96%) |
|FIRST INCIDENCE | 345 167 254 142 169 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.218N P=0.525N P=0.459N P=0.421N P=0.258N |
|POLY 3 | P=0.252N P=0.359N P=0.798N P=0.973 P=0.254N |
|POLY 1.5 | P=0.140N P=0.327N P=0.635N P=0.894N P=0.154N |
|POLY 6 | P=0.424N P=0.377N P=0.985N P=1.000 P=0.415N |
|LOGISTIC REGRESSION| P=0.158N P=0.408N P=0.479N P=0.710 P=0.174N |
|COCH-ARM / FISHERS | P=0.054N P=0.339N P=0.500N P=0.500N P=0.080N |
|ORDER RESTRICTED | P=0.091N (e) (e) (e) (e) |
|=================================================================================================================================|
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Number of tumor-bearing animals / Poly-3 number
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death.
Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fishers exact tests compare directly the overall incidence rates
For all tests a negative trend is indicated by N
(e) Value of Statistic cannot be computed.
(g) Poly-3 adjusted lifetime tumor incidence.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).